Sigma Life Science has added new genetically modified cancer cells to the company's range of quality cell lines.
These human knockout and knock-in oncology cell lines, created using Sigma's proprietary Compozr Zinc Finger Nuclease (ZFN) technology, offer researchers cellular models of cancer that are expected to enhance development of drugs for personalised medicine.
Sigma's Compozr Oncology Disease Model cell lines are designed to enable basic research and high-content, high-throughput screening of compounds and biologics.
The company believes that these cell lines will accelerate the development of personalised medicine through target validation, identification of mechanistic actions of drugs and investigation of disease development, progression and remission.
This product should enable researchers to study the effect of the mutation in its natural genomic context, using isogenic parental cells to help evaluate specific modifications without complications arising from background mutations.
The company will start its offering with cell lines that model colorectal and lung cancer.
Later this year, this portfolio of disease model cell lines is expected to expand with the introduction of a panel of genetically modified cell lines that model breast cancer.
